Glenmark Pharmaceuticals has submitted a copy of Press Release dated May 19, 2016 titled ‘Glenmark Pharmaceuticals receives ANDA approval for Rufinamide Tablets USP, 200 mg and 400 mg’.
The above information is a part of company’s filings submitted to BSE.